Protein Pathways plans a three-phased strategy in becoming the leader in the development and application of computational methods for drug discovery. The Company will leverage its revolutionary new technologies through three parallel business strategies.
In the first, the Company is using ProNexus and its related REDD platform for rational drug discovery, to discover and patent suitable drug targets, markers, and drug leads. Secondly.
Protein Pathways has developed Microbial ProNexus of protein interactions and the Database of Interacting Proteins (DIP) and is licensing these products to pharmaceutical and biotechnology companies. Thirdly, the Company will internally develop next-generation drugs to its own proprietary targets.